ArticleBMC psychiatry2025
Real-world evaluation of change in depressive symptoms among patients with treatment-resistant depression treated with esketamine.
Article in BMC psychiatry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTreatment-resistant depression (TRD) is often characterized by inadequate response to ≥ 2 oral antidepressant treatments of adequate dose and duration during a major depressive episode (MDE). Esketamine nasal spray (ESK) was approved by the US Food and Drug Administration in 2019 for TRD in conjunction with an oral antidepressant under a Risk Evaluation and Mitigation Strategy ( https://www.spravatorems.com/ ). While there are extensive clinical trial data demonstrating the efficacy and safety of esketamine use in TRD, the real-world data are limited. This study evaluated the change in depressive symptoms following esketamine initiation among patients with TRD in real-world settings.
methodsPatients with TRD treated with esketamine between 2019 and 2022 were identified from the PremiOM™ Major Depressive Disorder (MDD) Dataset, which includes > 440,000 patients in the US with linked claims and electronic medical record (EMR) data. Depressive symptoms were assessed using the 9-item Patient Health Questionnaire (PHQ-9). Baseline scores were within 6 months prior to the first esketamine prescription ("index date") and were compared to the most recent scores at > 0-3-months and > 3-6 months after index.
results163 patients were included (mean age 49.5 years, 58.3% female). Among patients with baseline and follow-up scores, statistically significant reductions in mean PHQ-9 scores were observed at > 0-3 months of -3.2 points, (95% CI: -4.5, -2.0; p < 0.001); and > 3-6 months of -4.4 points (95% CI: -5.7, -3.2; p < 0.001). The percentage of patients with moderately severe or severe depression at baseline was 55.8%. This decreased to 37.1% at > 0-3 months and 25.0% at > 3-6 months. Concomitantly, the percentages of patient with minimal depression and patients with mild to minimal depression increased.
conclusionsAmong patients with TRD treated with esketamine in real-world settings, significant improvements in depressive symptoms were observed over the six months following treatment initiation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.